Strata Critical Medical, Inc. (SRTA) Stock Analysis

Strata Critical Medical (SRTA) holds several notable competitive advantages in the U.S. organ transport and medical logistics sector. First, it operates the nation’s largest integrated air and ground network for transplant logistics, with approximately 30 dedicated aircraft and over 50 ground vehicles. This scale enables rapid response and reliability, which are critical in time-sensitive organ transport—an area where smaller rivals such as Paragonix and TransMedics lack comparable national reach or multimodal capacity.

SRTA’s “one-call” integrated platform, covering air, ground, surgical recovery, and organ placement, simplifies a complex process for hospitals and Organ Procurement Organizations (OPOs). This end-to-end model is unique among competitors, most of whom offer only a subset of these services.

Customer retention is high, with a reported 100% contracted customer retention rate over the last twelve months, indicating strong satisfaction and switching costs. The company’s asset-light approach—leveraging both owned and third-party aircraft—provides flexibility and cost control, supporting flight margins of 23.7% in 2024, up from 18.7% in 2023.

SRTA’s recent acquisition of Keystone Perfusion expands its clinical services and deepens its bench of specialized staff, addressing industry-wide shortages of perfusionists. The company’s strong balance sheet (over $75 million in cash, no debt as of Q3 2025) positions it to pursue further roll-up opportunities in a fragmented market, reinforcing its scale and service breadth.